KalVista Pharmaceuticals (KALV) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.
Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.
Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.
The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.
Shares of the company were down about 2% in recent trading.
Price: 12.01, Change: -0.24, Percent Change: -1.96
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。